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ARTICLE
Efﬁcacy of a respiratory syncytial virus vaccine
candidate in a maternal immunization model
Jorge C.G. Blanco1, Lioubov M. Pletneva1, Lori McGinnes-Cullen2, Raymonde O. Otoa1, Mira C. Patel1,
Lurds R. Fernando1, Marina S. Boukhvalova1 & Trudy G. Morrison2
Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis in infants.
Maternal immunization is an option to increase maternal antibody levels and protect infants
from infection. Here we assess the efﬁcacy of virus-like particle (VLP) vaccine candidates
containing stabilized pre-fusion (pre-F) or post-fusion (post-F) conformations of the RSV F
protein and the attachment RSV G protein in a maternal immunization model using cotton
rats. VLP vaccines containing RSV F and G proteins strongly boost pre-existing RSV immunity
in dams preventing their perinatal drop in immunity. Boosting is stronger for the pre-F VLP
than for the post-F VLP or puriﬁed subunit F protein vaccines, giving an advantage on
mothers’ protection. VLP immunization of dams provides signiﬁcant protection to pups from
RSV challenge and reduced pulmonary inﬂammation. Collectively, our results show that a
VLP vaccine with RSV F and G proteins is safe and effective for maternal and adult
vaccination.
DOI: 10.1038/s41467-018-04216-6 OPEN
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Maternal vaccination against infections that affectmothers and infants is now routine and includes vac-cines against inﬂuenza, tetanus, and pertussis. However,
a maternal vaccine for respiratory syncytial virus (RSV) is not
available in spite of a signiﬁcant need. RSV is the single most
important cause of acute viral respiratory disease in infants and
young children frequently resulting in hospitalization of infants in
the US and in signiﬁcant mortality rates in developing countries1.
Global RSV-associated acute lower respiratory infections in
children under age 5 accounts for ~33 million cases annually with
~10% of them resulting in hospitalization and an in-hospital
mortality rate of ~1–3%2.
Maternal transfer of RSV immunity to infants is likely pro-
tective during the ﬁrst months of life since the level of RSV
immunity in mothers during the last trimester of pregnancy and
the time of delivery correlates with levels of protection of infants3.
Thus, increasing maternal RSV immunity during pregnancy
could potentially extend the time of protection of their infants.
Moreover, recent evidence from human studies and experimen-
tally corroborated by us4–6 suggested that the period just prior to
delivery may be accompanied by a transient drop in immunity in
pregnant females. This ﬁnding suggests a window of vulnerability
in pregnant mothers that may need to be considered during the
rational design of RSV maternal vaccines. Thus, a maternal RSV
vaccine that could beneﬁt both mothers and infants would be
desirable.
A complication for development of a maternal RSV vaccine is
that the vast majority of humans has experienced RSV infection
by 2–5 years of age7. While naturally occurring pre-existing
immunity is incompletely protective, it could well impact the
effectiveness of a vaccine. Thus, a successful vaccine candidate
must stimulate high titers of neutralizing antibody (NA) in the
face of pre-existing immunity. Model animal systems using naive
animals are instrumental in initial immunogenicity, safety, and
efﬁcacy vaccine studies, but may be suboptimal for directly
mimicking human responses to RSV vaccines, which will virtually
always be in the context of previous exposure(s).
Use of live attenuated virus vaccines, which might overcome
pre-existing immunity, are not recommended by regulatory
entities to be used during pregnancy due to safety concerns.
Virus-like particles (VLPs) are increasingly recognized as a safe
and effective platform for developing vaccines against viral dis-
eases8. VLPs are virus-sized particles composed of repeating
structures on their surfaces and in their cores, structures that
mimic those of infectious viruses, which contribute to VLPs’
immunogenicity. VLPs are formed by assembly of viral structural
proteins and sometimes lipids into particles without the incor-
poration of the viral genome. Thus, VLPs are incapable of
replication. The surface glycoproteins of enveloped viruses are
folded and inserted into VLP membranes typical of an infectious
virus, thereby retaining antigenic epitope conformation.
We have recently described a Newcastle disease virus (NDV)-
based VLP vaccine against RSV that stimulates safe and protec-
tive immune responses in mice and in cotton rats9,10. In addition,
we have also demonstrated that cotton rats are a good model for
testing the efﬁcacy and safety of maternal vaccination against
RSV6,11.
Here we show the effect of previous RSV infection on induc-
tion of anti-RSV immunity by immunization with VLPs con-
taining different conformational forms of the RSV F protein and
the G protein in cotton rat females during gestation, and the
ability of these vaccines to provide protection from RSV challenge
of offspring. VLP immunization signiﬁcantly increases NA titers
in both RSV-seropositive pregnant females and their litters.
Importantly, litters of these animals are notably better protected
from RSV replication in the lungs than offspring of RSV naive,
vaccinated animals. Furthermore, the transient immunosuppres-
sion in pregnant females shortly before delivery is prevented by
VLP immunization. Pulmonary protection and serology in pups
is more robust in animals vaccinated with VLPs than animals
vaccinated with puriﬁed F proteins. Pre-F protein-containing
VLPs provide an immunologic advantage to dams and afford a
moderate improvement in nasal protection of pups compared to
post-F-containing VLPs or to vaccine preparations comprised of
puriﬁed subunit F protein.
Results
Properties of VLPs used for immunization. VLPs used for
immunization are based on NDV core nucleocapsid (NP) and
matrix (M) proteins and contain the ectodomain of the RSV G
protein and the stabilized pre-fusion or post-fusion forms of the
RSV F protein. These VLPs were produced in avian ELL-0 cells as
previously described12 to generate stocks of VLP-H/G+ Pre-F/F
or VLP-H/G+ Post-F/F (abbreviated as Pre-F VLP and Post-F
VLP, respectively)9,13. The RSV F and G protein content and RSV
F protein conformation in the two puriﬁed VLP preparations
were quantiﬁed and characterized by western analysis and anti-
body binding to the puriﬁed VLPs (Supplementary Figs. 1–3)9,13.
In addition, the soluble post-F and pre-F proteins used for vac-
cination in this study were characterized by binding to form-
speciﬁc monoclonal antibodies and quantiﬁed by western analysis
(Supplementary Fig. 4).
Infection and immunization. To study vaccine efﬁcacy in naive
and pre-exposed animals, one set of female cotton rats was
primed by intranasal (i.n.) RSV infection (RSV primed), while a
second set of animals was not RSV primed (naive) (Fig. 1 and
Supplementary Table 1). All animals were set up for breeding and
vaccinated during pregnancy with VLPs containing G and pre-F
or post-F proteins intramuscularly (i.m.). Additionally, vaccina-
tions with puriﬁed F proteins in pre-F or post-F conformation
were also included to immunize pregnant females for compar-
ison. All vaccinations were performed once using equal amount
of F protein in the preparations (10 μg). Control animals in both
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Fig. 1 VLP immunization of naive and RSV-primed female cotton rats.
Diagram of the animal protocol. Female cotton rats were primed by i.n.
infection with RSV A/Long (105 PFU i.n.) or left unprimed. Eight weeks
later, all females were set in breeding pairs with naive males. At week 10
(the time called "before vaccination", B.V.), primed and unprimed females
were divided into groups of animals that were mock-immunized,
immunized i.m. with different VLPs, F protein preparations, or with live RSV
i.m. Pup delivery started on week 12 (time called "before delivery", B.D.).
All pups were challenged with RSV at 4 weeks of age, and sacriﬁced 4 days
later
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sets were mock-immunized or inoculated i.m. with live RSV, an
established positive control for protective RSV immunity11. Pups
from all females were infected with RSV at 4 weeks of age and
then sacriﬁced 4 days later to assess the protective efﬁcacy and
safety of the maternal vaccinations. Four weeks of age was
selected for RSV challenge of pups based on the earlier studies
that demonstrated that maternally transferred RSV immunity
signiﬁcantly wanes in cotton rat pups between 1 and 4 weeks after
birth, yet remains detectable11. Thus, 4 weeks of age is optimal for
evaluation of the extent to which maternal immunity to RSV
vaccine candidates transferred to pups. Serum samples were
obtained from dams at intervals indicated in Supplementary
Fig. 5 and 6, and from pups at 4 weeks of age, just before chal-
lenge with RSV.
NA in RSV-primed and naive animals. RSV NAs in dams were
quantiﬁed by plaque reduction assay (Figs. 2–3, Supplementary
Figs. 5, 6). Before vaccination (B.V., week 10), RSV-primed
females consistently showed increased level of RSV NA antibody
titers at ~7.1 ± 0.2 Log2 (mean ± standard error (s.e.m.), n= 55,
Supplementary Fig. 5).
Primed and unprimed females were immunized on week 10 as
indicated in Fig. 1 in six different vaccination groups.
Supplementary Fig. 6 shows the distribution of RSV NA titers
for all female cotton rats (unprimed, back symbols; RSV-primed,
red symbols), according to the different vaccination groups.
Serum samples were obtained before vaccination (week 10, B.V.)
and then ≥2 weeks after vaccination, but <1 week “before
delivery” (week 12, B.D.). Additional serum samples from the
females were collected on weeks 13, 14, and 16 post-priming.
All animals primed and mock-vaccinated showed a reduction
in their RSV NA titers in serum samples taken on week 12 (Fig. 2,
Supplementary Fig. 6, Mock, arrow), when compared with serum
samples obtained on week 10, supporting our previous observa-
tions of a drop in maternal immunity shortly before the time of
delivery6. Unprimed cotton rats (black bars) strongly responded
to all VLP vaccinations, and in the case of Pre-F VLP, produced
RSV NA titers similar to those induced in female cotton rats
vaccinated with live virus, i.m. (Fig. 2, Supplementary Fig. 6). In
primed animals (red bars), VLPs containing the pre-fusion or
post-fusion form of the F protein induced higher levels of RSV
serum NA before delivery (week 12) than in RSV-primed animals
vaccinated with RSV i.m. Importantly, in comparing the RSV NA
titers before vaccination (10 wks) vs. NA titers before delivery (12
wks), female cotton rats in all vaccination groups did not exhibit
the drop in NA previously seen in RSV-primed, mock-vaccinated
animals6 (Fig. 2 top right panel and Supplementary Fig. 6).
Moreover, in the case of VLP and F protein vaccination, we
observed a boost of the RSV NA after delivery (12 wks), which
was particularly robust and sustained in animals immunized with
VLPs containing the pre-F protein (Fig. 2 right panels, Pre-F and
Supplementary Fig. 6).
The increased boosting of pre-existent immunity by pre-F
VLPs or pre-F protein, however, was transient, exhibiting
maximum effect 2–3 weeks after immunization, and subsiding
thereafter (Fig. 2 and Supplementary Fig. 6). The strong transient
increase in NA induced by pre-F VLPs was not as apparent for
post-F VLPs, pre-F, and post-F proteins, or RSV i.m. immuniza-
tion (Supplementary Fig. 6).
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Fig. 2 RSV serum neutralizing antibodies measured in dams. RSV-primed
(right panels, red bars) or unprimed (left panels, black bars) females were
bled at the indicated times post-priming. Each bar represent the mean ± s.e.
m. of each vaccination group. At each time point, comparison of the NA
between the respective mock-vaccinated group and VLPs, F proteins, or
RSV-i.m.-vaccinated groups was assessed by one-way ANOVA followed by
Tukey post hoc test. *p < 0.05, **p < 0.005, ***p < 0.001, #p < 0.0005, +p
< 0.0001. Week 10 samples represent sera taken before vaccination (B.V.),
whereas week 12 samples represent sera taken before delivery (B.D.) of
pups
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To quantify the extent of immunity induction/boost by each
vaccine, serum RSV NA titers were compared in all females
before vaccination (wk 10) and before delivery (Fig. 3). In
unprimed animals, vaccination with VLPs led to an increase of
mean NA in the female cotton rats of about 2–3 Log2, comparable
to that induced by vaccination with RSV i.m., whereas
vaccination with soluble F proteins did not. However, in RSV-
primed females, those vaccinated with VLPs or puriﬁed F
proteins displayed a signiﬁcantly stronger increase of RSV NA
titers compared to the group of females vaccinated i.m. with live
RSV (ANOVA followed by Tukey post hoc test, +, p= 0.0001 for
pre-F VLPs). Animals vaccinated with pre-F VLP performed
signiﬁcantly better (ANOVA followed by Tukey ad hoc test,
p < 0.05) than animals vaccinated with post-F VLPs or puriﬁed F
proteins. These data indicate that vaccines containing F protein
administered during pregnancy can signiﬁcantly boost NA titers
in RSV-primed animals, surpassing live RSV i.m. vaccination in
that regard, and that pre-F VLPs may outperform post-F VLPs
and F protein subunit vaccines preparations in their boosting
ability.
Total anti-F and anti-G antibody IgG titers. Maternal anti-pre-
F, anti-post-F, and anti-G protein IgG antibodies generated in
each of the groups of animals were measured by antigen-speciﬁc
ELISA assays (Fig. 4 and Supplementary Fig. 7). Unprimed
females vaccinated during pregnancy showed strong induction of
both anti-pre-F protein and anti-post-F protein antibodies
(Fig. 4a, b). As previously reported10, levels of total pre-F-speciﬁc
antibodies were slightly lower than levels of post-F-speciﬁc
antibodies in unprimed animals, even the ones immunized with
pre-F. Levels of anti-G protein antibodies were also strongly
induced by VLP vaccination, whereas only low levels were
detectable in animals immunized i.m. with live RSV (Fig. 4c).
RSV-primed females showed elevated levels of IgG against
both, pre-F and post-F targets before vaccination. These animals
(Fig. 4d–f) demonstrated a strong boost of total antibodies
speciﬁc for the pre-F target, post-F target, and G protein. Pre-F
VLP immunization resulted in a signiﬁcantly higher titers of pre-
F-speciﬁc antibodies than post-F VLP immunization, consistent
with the stimulation of pre-F-speciﬁc memory responses
(Supplementary Fig. 7). In contrast, immunization with the pre-
F VLPs and the post-F VLPs resulted in similar levels of
antibodies speciﬁc for the post-F protein, a result consistent with
previous observations that both pre-F and post-F proteins can
induce post-F-speciﬁc antibodies.
Importantly, the transient drop in maternal NA titers that
occurs shortly before delivery in RSV-primed, mock-vaccinated
animals was also seen in both the F-speciﬁc and G-speciﬁc
binding IgG ELISA analysis (Fig. 4d, e, f, arrowheads).
Vaccination of pregnant seropositive females with either live
RSV i.m. or with any of the VLPs tested prevented this decline in
anti-RSV antibody levels in the females before delivery.
There is no difference in the ability of VLPs and soluble F
proteins to stimulate memory responses for total anti-F-IgG
(Fig. 4g, h). However, VLPs much more efﬁciently induced total
anti-F IgG in naive animals than soluble F protein. Interestingly,
there was a clear effect of vaccine format (puriﬁed protein vs.
VLP) on the ability of pre-F to induce IgG. For example, soluble
pre-F administered to unprimed animals induced higher levels of
IgG reactive with either pre-F or post-F target, compared to
soluble post-F. In the context of VLPs, however, pre-F and post-F
were comparable in their ability to induce pre-F and post-F
reactive antibodies.
Serum NA in offspring after maternal vaccination with VLPs.
Cotton rat litters born to unprimed or primed dams vaccinated
once with different VLPs, soluble F proteins, or with live RSV
administered i.m. were tested for the presence of maternal RSV
NA 4 weeks after birth. Litters born to unprimed dams vaccinated
with pre-F VLPs showed signiﬁcant levels of maternal RSV NA
remaining in circulation (Fig. 5a, black symbols) compared to
animals born to naive, mock-vaccinated dams. Pups born to RSV-
primed dams (Fig. 5a, red symbols) vaccinated with pre-F-
containing VLPs showed signiﬁcant enhancement in the
remaining maternal NA (~0.7 Log2 increase) compared to ani-
mals born to primed, mock-vaccinated dams. Pups born to
primed dams vaccinated with RSV i.m., VLPs containing post-F,
or soluble pre-F or post-F vaccines did not show signiﬁcant
increase in the remaining levels of RSV NA when compared to
primed, mock-vaccinated dams. These data demonstrate that
maternal vaccination using pre-F VLPs signiﬁcantly enhanced the
levels of RSV NA in their litter measured at 4 weeks of age, and
that the post-F VLPs and the puriﬁed proteins were insufﬁcient
for that purpose.
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Protection of offspring from RSV after maternal vaccination.
Litters born to unprimed or primed female cotton rats vaccinated
with different VLPs, soluble F proteins, or RSV i.m. were chal-
lenged with RSV to evaluate the degree of protection remaining at
4 weeks of age. A small but signiﬁcant reduction (ANOVA fol-
lowed by Tukey post hoc test; +p= 0.0001) in viral titers in the
lungs was seen in all litters born to unprimed dams vaccinated
with VLPs or with RSV i.m. compared to pups of unprimed,
mock-vaccinated dams (Fig. 5b, black symbols). However, no
differences in protection were seen between groups born to
unprimed, mock-vaccinated dams, and litters born to dams
vaccinated with puriﬁed F proteins. In contrast, vaccination of
primed dams with VLPs or puriﬁed F proteins signiﬁcantly
improved protection of their litters (Fig. 5b, red symbols) from
RSV challenge, while live RSV i.m. immunization did not. In
VLP-vaccinated groups, some litters showed full protection of the
lung (Fig. 5b), whereas none of the litters born to dams vacci-
nated i.m. with the puriﬁed F proteins (pre-F or post-F) or with
live RSV achieved that level of protection. No signiﬁcant differ-
ence in protection between pups of RSV-primed, pre-F, or post-F
VLP-vaccinated dams was observed (Fig. 5b).
Protection of the nose by VLP vaccinations was more modest
than protection of the lungs (Fig. 5c). However, two litters born to
RSV-primed dams immunized with pre-F VLP had signiﬁcantly
reduced levels of virus in their noses compared to litters born to
primed dams immunized with puriﬁed pre-F or post-F (Fig. 5c).
Lung pathology and inﬂammatory cytokines in litters post
challenge. Next we examined whether vaccination of female
cotton rats during pregnancy with VLPs could also beneﬁt the
litter by decreasing the lung pathology associated with primary
RSV infection. Hematoxylin and eosin-stained lung sections were
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scored for RSV-induced lesions as previously described6. A sig-
niﬁcant reduction in peribronchiolitis, a common marker of RSV-
related pathology in the cotton rat, was evidenced in animals that
were born to primed and vaccinated dams (Fig. 6, red symbols,
non-parametric Kruskal–Wallis test). Importantly, animals born
to unprimed dams vaccinated with pre-F and post-F VLPs
showed a signiﬁcant reduction in interstitial pneumonia and
alveolitis when compared to pups born to unprimed dams that
were mock-vaccinated during pregnancy (Fig. 6, black symbols,
non-parametric Kruskal–Wallis test).
Enhanced lung mRNA expression for selected cytokines has
been associated with the presence of increased lung pathology in
many RSV vaccination and challenge studies. Since we found a
reduction of lung pathology in cotton rats born to primed and
vaccinated dams, we extended our analysis to determine if
expression of these lung cytokines was also reduced. IL-6, a
cytokine directly induced by viral replication, showed a dramatic
decrease in lung expression in pups born to primed and VLPs-
vaccinated cotton rat mothers (Fig. 7, red symbols) compared to
pups born to mock-vaccinated animals. This result strongly
correlates with the reduction in RSV lung viral titer (Fig. 5b) and
lung histopathology (Fig. 6) and indicates that vaccination with
VLPs during pregnancy not only reduces viral titers but also
suppresses lung inﬂammation and histopathology during RSV
infection. Furthermore, expression of IFN-γ was also reduced in
animals born to primed and VLP-vaccinated dams (Fig. 7, red
symbols), showing a greater decrease than seen in pups born to
the primed and RSV-i.m.-vaccinated dams. These data demon-
strate the safety of vaccination with VLPs during pregnancy in the
cotton rat model and corroborate the reduction of lung
inﬂammation in the same vaccinated groups.
Discussion
Infants under 6 months of age are highly susceptible to RSV
infection2. However, immunization of this population is proble-
matic for several reasons. First, the immune system of infants is
still immature, potentially resulting in an ineffective immune
response. Second, the historical failure and dangers of the
formalin-inactivated RSV vaccine increase the concern for safety
of RSV vaccination of the very young. Third, there have been
difﬁculties in generating live attenuated vaccines with the right
balance of immunogenicity and safety for the approval in this
population. Fourth, the effects of naturally transferred anti-RSV
maternal antibodies on the efﬁcacy of infant vaccination are
unknown.
Maternal vaccination could be a safe and effective approach to
protect infants from RSV infections. Using serum samples from a
cohort of children less than 145 months of age14, it was recently
shown that 100% of infants <1 month of age were seropositive for
RSV antibodies, whereas the lowest seroprevalence (25%) was
found in infants between 6 and 7 months old. Subsequently, due
to natural RSV infection, the percentage of RSV-seropositive
infants increased to ~40% by 1 year of age, and reached 100%
again by 3 years14. Although results of this study might not be
generalizable to other infant populations, the authors suggest that
the window of RSV susceptibility during infancy has relatively
well-deﬁned limits that could be narrowed, at least from one side,
by maternal immunization. Thus, a maternal vaccine that could
increase and prolong protective antibody levels in the babies
could become a routine component of prenatal care.
Several non-replicative RSV vaccine candidates for maternal
immunization are currently in clinical trials15,16. However, their
efﬁcacy in reducing viral replication, extending protection, and
reducing disease in the offspring have not been deﬁned or
quantiﬁed. Surrogates of protection for RSV vaccines during
pregnancy are difﬁcult to deﬁne since many variables affect the
level of protection required for infants at the time of the
encounter with virus. The level of maternal antibodies during
pregnancy, or more importantly, during the last trimester of
pregnancy, has been one of the most important parameters that is
indicative of beneﬁt to infants3. However, maternal antibodies
decay rapidly in infants after birth, and thus their beneﬁt in
subsequent months of life depends on the amount and quality
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received from the mother before delivery or during lactation17. In
addition, we have reported previously the negative effect that pre-
existent RSV immunity has on RSV maternal vaccination11,18.
Thus, in this study, we explored the boosting capacity of VLP
vaccination on pre-existent maternal immunity and its sub-
sequent transfer to offspring.
In cotton rats, we previously deﬁned the threshold period of
4 weeks post birth as the time when protection imparted by RSV-
primed dams goes from strong to negligible11. The experiments
described here were designed based on these previous observa-
tions with the purpose of identifying the best vaccine candidate
that can extend protection of immunologically naive cotton rat
pups past this 4-week threshold.
Our results show that VLPs containing RSV F and G proteins
were highly effective at enhancing pre-existing maternal RSV
immunity and provided extended protection to progeny with only
one immunization during pregnancy. We observed a signiﬁcant
increase in serum NA against RSV in dams only 2 weeks post
vaccination in VLPs-vaccinated groups (Figs. 2–3, and Supple-
mentary Fig. 6). This study was performed using a ﬁxed vacci-
nation schedule set at the theoretical mid-term of pregnancy in
cotton rats. Further studies will be required to optimize the
timing of maternal vaccination with the goal of enhancing pro-
tection of the pups from RSV challenge.
The enhancement of RSV NA titers by vaccination of naive
females was lower than expected, likely due to the short window
of time used for evaluation, 2 weeks, the fact that it was a single
immunization, and/or the negative effect of pregnancy on the
levels of NA. However, unprimed females were important con-
trols for our study since they demonstrated that VLPs performed
better as vaccines in primed animals than in naive animals.
We previously demonstrated that RSV-primed animals
undergo a period of reduced RSV immunity that was detected
around the time of delivery as evidenced by a drop in NA titers in
serum6. Now we report that IgG antibodies targeting both forms
of F protein and the G protein showed a decrease in titer in these
females, indicating that this drop is a generalized phenomenon
that is present in these animals before delivery. Although this
ﬁnding has not yet been corroborated in humans, there is recent
evidence that pregnancy is a time of increased RSV vulner-
ability4,5. However, we demonstrate that vaccination during
pregnancy with RSV i.m. or with either of the two different F-G
RSV VLP preparations overcome the transient immunosuppres-
sion that occurs shortly before delivery. We hypothesize that
vaccination during pregnancy could reload and/or maintain the
pool of maternal anti-RSV antibodies, thus beneﬁting the mothers
and also increasing the levels of antibodies transferred to the fetus
through the placenta and/or through nursing.
Pre-F-containing VLPs were found to be signiﬁcantly more
efﬁcient than the post-F VLPs vaccine or the puriﬁed F protein
vaccines in boosting pre-existent RSV NA in primed female
cotton rat (Fig. 3). Pre-F VLPs also enhanced the levels of NA
transferred to litters, in addition to the protection of the lung
from RSV replication (Fig. 5b). Furthermore, the protection of the
nose in the challenged pups of primed dams vaccinated with pre-
F VLPs showed improvement in the protection of several dif-
ferent litters (Fig. 5c). Although this result did not achieve sta-
tistical signiﬁcance when litters from primed, mock-vaccinated
animals were compared, the improvement was signiﬁcant when
compared to litters from dams primed and vaccinated with the
puriﬁed F protein preparations. This result could certainly
depend on the pre-existent repertoire of B and T cells to be re-
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stimulated by the vaccine. The reasons why the difference in
immune responses in dams to the pre-F and the post-F was not
signiﬁcantly translated into an increased transfer of NA and
differences in the lung protection in offspring are unknown and
will be the subject of future investigations.
Human studies have estimated the half-life of maternally
derived anti-RSV antibodies to be between 28 and 80 days,
depending on the study19–22, whereas the half life of cotton rat
antibodies is ~7 days18. Since in this study we tested NA titers in
cotton rats at 4 weeks of age, theoretically four half-lives passed
by the time of challenge. The levels of RSV NA antibodies in pups
of primed dams vaccinated with VLPs at 4 weeks (~5.5 Log2)
were signiﬁcantly higher than those in pups of primed, mock-
vaccinated dams, suggesting that in humans these VLP vaccines
could potentially elicit enhanced and uniform protection of
babies beyond the 6th month.
Overall our data demonstrate that RSV F/G VLP vaccination of
cotton rats during pregnancy robustly stimulates pre-existent
RSV immunity with only one immunization, provides enhanced
protection of offspring, and reduces pulmonary inﬂammation in
the pups normally associated with RSV infection. Comparison of
vaccination with VLPs vs. equivalent concentrations of the pur-
iﬁed F show superiority under the conditions tested and further
emphasize the potential of VLP platform to improve vaccine
efﬁcacy.
Methods
VLP preparation and characterization. VLPs containing the RSV F and G pro-
teins were formed with the NDV core proteins NP and M23,24. The cDNAs
encoding the NDV NP and M protein have been previously described25. The RSV
G and F proteins were incorporated into these VLPs by constructing chimera
protein genes composed of ectodomains of the G or F glycoproteins fused to the
transmembrane and cytoplasmic domains of the NDV HN protein or NDV F
glycoprotein, respectively, to generate H/G and F/F chimera proteins. The NDV
domains speciﬁcally interact with the NDV NP and M protein resulting in efﬁcient
incorporation of the chimera proteins into VLPs. The construction and expression
of the chimera protein NDVHN/ RSVG (H/G), the stabilized chimera pre-fusion F
protein (DS Cav1 pre-F/F), and the stabilized chimera post-fusion F protein (post-
F/F) have been previously described9.
For preparations of VLPs to be used as immunogens (VLP-H/G+ Pre-F/F,
VLP-H/G+ Post-F/F), ELL-0 cells (ATCC CRL-12203) growing in T-150 ﬂasks
were transfected with cDNAs encoding the NDV M protein, NP, the chimeric
proteins H/G, and either Pre-F/F or Post-F/F as previously described12,24. At 24 h
post-transfection, heparin (Sigma, H4784) was added to the cells at a ﬁnal
concentration of 10 μg ml[−1 11 to inhibit re-binding of released VLPs to cells. At
72, 96, and 120 h post-transfection, cell supernatants were collected and VLPs
puriﬁed by sequential pelleting and sucrose gradient fractionation as previously
described8,12,24. Concentrations of proteins in the puriﬁed VLPs were determined
by silver-stained polyacrylamide gels and by western blot analysis using marker
proteins for standard curves8,24. The conformation of F protein in the VLP
preparations was veriﬁed by reactivity to mAbs as previously described8,24.
Preparation of soluble F and G proteins. The constructions of genes encoding the
soluble pre-F protein, the soluble post-F protein, and the soluble G protein used for
target in ELISA were previously described9. For preparation of these soluble pro-
teins, expi293F cells (ThermoFisher A14527) were transfected with pCAGGS
vector containing sequences encoding the soluble proteins. At 5–6 days post
transfection, total cell supernatants were collected and cell debris removed by
centrifugation. Pre-fusion F, post-fusion F, and G polypeptides were then puriﬁed
on columns using the His tag and then the strep tag as previously described26.
ELISA protocols. For ELISA, wells of microtiter plates (ThermoFisher/Costar
2797) were coated with either puriﬁed soluble pre-fusion F protein, soluble post-
fusion F protein, or soluble G protein and incubated for 24 h at 4 °C. Wells were
then incubated in PBS-2% BSA for 16 h. Different dilutions of sera, in 0.05% Tween
and 2% BSA, were added to each well and incubated for 2 h at room temperature.
After six washes in PBS, sheep anti-mouse antibody coupled to HRP (Sigma
A5906) was added in 50 μl PBS-2% BSA and incubated for 1.5 h at room tem-
perature. Bound HRP was detected by adding 50 μl TMB (3,3′5,5′-tetra-
methylbenzidin, ThermoFisher34028) and incubating for 5–20 min at room
temperature until blue color developed. The reaction was stopped with 50 μl 2N
sulfuric acid. Color was read in SpectraMax Plus Plate Reader (Molecular Devices)
using SoftMax Pro software. ELISA titers were deﬁned as the dilution of sera that
resulted in an optical density of 0.4, which was at least 20-fold over background as
in Fig. 3a–f. Results shown in panels g and h are ng ml−1 IgG calculated using a
standard curve of puriﬁed cotton rat IgG.
Animals. Sigmodon hispidus cotton rats were obtained from an inbred colony
maintained at Sigmovir Biosystems, Inc. (Rockville, MD). Three-week-old female
cotton rats were recruited for these studies, and randomly tagged and separated in
groups as indicated (Supplementary Table 1). Eight weeks later, females were
paired with males ~2 weeks older than the females for mating. Animals were pre-
bled before inclusion in the study to rule out the possibility of pre-existent anti-
bodies against RSV. The colony was monitored for antibodies to paramyxoviruses
and rodent viruses, and no such antibodies were found. All studies were conducted
under applicable laws and guidelines and after approval from the Sigmovir Bio-
systems, Inc. Institutional Animal Care and Use Committee. Animals were housed
in large polycarbonate cages and fed a standard diet of rodent chow and water ad
libitum. All cotton rats born as a result of breeding during these studies were used
for RSV infection at 4 weeks of age and are referred to as “pups”.
Viruses and viral assays. The prototype Long strain of RSV was obtained from
American Type Culture Collection (ATCC VR-26, Manassas, VA). Virus was
propagated in HEp-2 cells (ATCC CCL-23) due to their permissiveness, and
serially plaque-puriﬁed to reduce defective-interfering particles. The single pool of
virus containing 107.6 PFU/ml was used for all experiments. To adjust the dose,
stock aliquots were diluted with PBS for intranasal (i.n.) infections. Viral titers in
the lungs and in the nose of RSV-infected pups were determined as described
elsewhere11 and normalized for the weight and expressed as PFU gm−1 of tissue.
RSV NA assay. RSV NA titers were measured by 60% plaque reduction assay as
previously described27. In brief, 4-fold or 6-fold dilutions of heat-inactivated serum
samples were incubated with RSV/A/Long strain and inoculated onto HEp-2 cells.
After 4 days of incubation under 0.75% methylcellulose overlay, the overlay was
removed and the cells were ﬁxed and stained with crystal violet. Plaques were
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quantiﬁed and reciprocal NA titers were determined as previously described (the
limit of detection of this assay is 4.32 Log2)11.
Cytokine gene expression by real-time RT-PCR. Total RNA was extracted from
homogenized lung tissue using the RNeasy puriﬁcation kit (QIAGEN). One μg of
total RNA was used to prepare cDNA in a volume of 20 μl (QuantiTect Reverse
Transcription Kit from Qiagen). cDNA was diluted to 10 μg ml−1 and 3 μl were
used for each 25 μl real-time PCR reaction (QuantiFast SYBR Green PCR Kit from
Qiagen) with ﬁnal primer concentrations of 0.5 μM. Primer sequences for β-actin,
IFN-γ, and IL-6 are provided in Supplementary Table 2. Reactions were set up in
96-well plates and ampliﬁcations were performed on a Bio-Rad iCycler (MyiQ
Single Color). Delta Ct method was used to calculate relative gene expressions that
were normalized to β-actin as a housekeeping gene6,11.
Lung histopathology. Lungs were dissected and inﬂated with 10% neutral buffered
formalin to their normal volume, and then immersed in the same ﬁxative solution.
After ﬁxation, lungs were embedded in parafﬁn, sectioned, and stained with
hematoxylin and eosin (H&E). An average pathology score was determined for
each group based on four parameters of pulmonary inﬂammation: peribronchiolitis
(inﬂammatory cell inﬁltration around the bronchioles), perivasculitis (inﬂamma-
tory cell inﬁltration around the small blood vessels), interstitial pneumonia
(inﬂammatory cell inﬁltration and thickening of alveolar walls), and alveolitis (cells
within the alveolar spaces). Slides were scored blindly on a 0–4 severity scale as
previously described6.
Experimental design. Female cotton rats were bled and a subgroup of all female
used were primed by RSV A/Long infection using a dose of 105 PFU/animal (50 μl
per animal intranasally (i.n.)) (Fig. 1, Supplementary Table 1). At week 8, all
females were set up in breeding pairs with RSV-seronegative males. Females were
bled for serum collection at 4, 8, and 10 weeks post-priming. At week 10 (the time
generally corresponding to the middle of pregnancy) females were separated into
six additional groups and vaccinated i.m. with TNE (50 mM Tris-HCl, pH 7.4, 150
mM NaCl, 5 mM EDTA), VLPs containing the attachment RSV G protein and a
pre-fusion or a post-fusion form of the F protein (VLP Pre-F/G and VLP Post-F/G,
respectively); 100 μg of VLPs per animal and containing 10 μg of F protein and 10
μg of G protein per dose, puriﬁed pre-F protein (10 μg per animal), puriﬁed post-F
protein (10 μg per animal), or a control group vaccinated i.m. with live RSV A/
Long (105 PFU RSV per animal)11. Females started delivering pups after the week
12 post-priming. All pups were eye-bled, and challenged with RSV A/Long i.n.
(105 PFU per animal) at 4 weeks of age. On day 4 post infection, all pups were
sacriﬁced for analysis of nose and lung viral titers, lung histopathology, and
expression of mRNA corresponding to select Th1 and Th2 cytokines as previously
described28. An additional group of ﬁve females remained unprimed and unvac-
cinated. This group of females was used as a source of pups that remained unin-
fected, and provided basal levels of lung gene expression for comparison. Serum
samples were obtained from pups before RSV challenge. Dams were kept on the
study for ~5 weeks after delivery of pups for additional serum collection. The
results presented are collected from three independent experiments (XV-146, XV-
176, and XV-186).
Statistical analyses. For determination of serum NA titers in each group of
female cotton rats, mean ± s.e.m. was determine. Comparison of the indicated
groups was performed by one-way ANOVA followed by Tukey post hoc test. For
litters, values of viral titers, serum NA, cytokine mRNA expression, and histo-
pathology of pups in a litter were averaged and their mean ± s.e.m. were plotted.
Comparison between indicated groups was performed by one-way ANOVA fol-
lowed by Tukey post hoc test or non-parametric Kruskal–Wallis test, as indicated.
For analysis, KaleidaGraph 4.5 and GraphPad Prism 7.0c for Mac OS X were used.
Data availability. All data relevant to this study are available from the corre-
sponding author upon request.
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